scholarly journals Adenylyl cyclase‑associated protein�1‑targeted nanoparticles as a novel strategy for the treatment of metastatic non‑small cell lung cancer

2019 ◽  
Author(s):  
Yang Liu ◽  
Shuanshuan Xie ◽  
Jie Zeng ◽  
Xiaolian Song ◽  
Min Tan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Adenylyl Cyclase ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Targeted Nanoparticles ◽  
Novel Strategy

scholarly journals Development of paclitaxel loaded pegylated gelatin targeted nanoparticles for improved treatment efficacy in non-small cell lung cancer (NSCLC): an in vitro and in vivo evaluation study

2021 ◽  
Author(s):  
Minwei Gu ◽  
Jun Luan ◽  
Kun Song ◽  
Cao Qiu ◽  
XiaoLi Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lines ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Targeted Nanoparticles ◽  
Pulmonary Deposition

Purpose: To develop and evaluate paclitaxel (PTX) loaded pegylated gelatin targeted nanoparticles for improved efficacy in non-small cell lung cancer (NSCLC) treatment. Method: PTX loaded gelatin nanoparticles (PTX-GNP) were prepared by crosslinking with glutaraldehyde aqueous solution. These nanoparticles (NPs) were further incubated with PEG 400 to form PEGylated NPs (PEG-PTX-GNP). The NPs were evaluated for surface morphology, size, zeta potential, encapsulation efficiency, drug loading, in vitro drug release, cytotoxicity in an assay on cancer cell lines L132, in vitro cellular uptake in an assay in L132 and 293T cell lines, in vivo antitumor activity on female Balb/c mice, pulmonary deposition, histopathology, and immunohistochemical properties. Results: The nanoparticles were of spherical shape with smooth surface characteristics. The observed DL was of 20.18 to 32.11%, as particle size was of 90 to 115 nm. Zeta potential and polydispersity index (PDI) were within acceptable ranges. Encapsulation was effective when the NPs had a size of 80.50 nm to 98.12 nm. The PEGylated PTX loaded nanoparticles (PEG-PTX-GNP, GNP4) showed similar PTX release profile to that of the NP4 formulation. PEGylated NPs showed the desired PTX release pattern that is required for cancer treatment. In an in vitro cytotoxicity study, PEG-PTX-GNP showed the maximum antiproliferative activity over the period of 24 hours, followed by PTX-GNP, pure PTX and BPEG-GNP. PEG-PTX-GNP showed the highest internalization within both cell lines, followed by PTX-GNP and pure PTX. The survival rate of animals in PEG-PTX-GNP group was 100%, proving the safety and efficacy of the treatment. PEG-PTX-GNP showed the highest antitumor activity as compared to other formulations. The pulmonary deposition rate was the highest (6.5 to 12.55 μg/g) in PEG-PTX-GNP formulations. Histopathology and immunohistochemical study proved that PEG-PTX-GNP had greater anticancer potential than other tested formulations. Conclusion: This study confirms the potential use of paclitaxel loaded PEGylated gelatin targeted nanoparticles for improved efficacy in non-small cell lung cancer (NSCLC) treatment.

Poly(ester-thioether) microspheres co-loaded with erlotinib and α-tocopheryl succinate for combinational therapy of non-small cell lung cancer

2020 ◽  
Vol 8 (8) ◽  
pp. 1728-1738 ◽  
Author(s):  
Furong Cheng ◽  
Xinyu Peng ◽  
Guolong Meng ◽  
Yuji Pu ◽  
Kui Luo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Combination Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Combinational Therapy ◽  
Tocopheryl Succinate ◽  
Novel Strategy

We report erlotinib and α-TOS combination as a novel strategy for therapy of NSCLC and poly(ester-thioether) microspheres as a robust depot for their local combination therapy.

Sign in / Sign up

Export Citation Format

Share Document